Abstract
Our intestinal microbiota serve many roles vital to the normal daily function of the human gastrointestinal tract. Many probiotics are derived from our intestinal bacteria, and have been shown to provide clinical benefit in a variety of gastrointestinal conditions. Current evidence indicates that probiotic effects are strain-specific, they do not act through the same mechanisms, and nor are all probiotics indicated for the same health conditions. However, they do share several common features in that they exert anti-inflammatory effects, they employ different strategies to antagonize competing microorganisms, and they induce cytoprotective changes in the host either through enhancement of barrier function, or through the upregulation of cytoprotective host proteins. In this review we focus on a few selected probiotics – a bacterial mixture (VSL), a Gram-negative probiotic (E. coli Nissle 1917), two Gram-positive probiotic bacteria (LGG, L.reuteri), and a yeast probiotic (S. boulardii) – for which sound clinical and mechanistic data is available. Safety of probiotic formulations is also discussed.
Keywords: Probiotics, intestinal microbiota, inflammation, colitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science
Volume: 8 Issue: 3
Author(s): Elaine O. Petrof
Affiliation:
Keywords: Probiotics, intestinal microbiota, inflammation, colitis
Abstract: Our intestinal microbiota serve many roles vital to the normal daily function of the human gastrointestinal tract. Many probiotics are derived from our intestinal bacteria, and have been shown to provide clinical benefit in a variety of gastrointestinal conditions. Current evidence indicates that probiotic effects are strain-specific, they do not act through the same mechanisms, and nor are all probiotics indicated for the same health conditions. However, they do share several common features in that they exert anti-inflammatory effects, they employ different strategies to antagonize competing microorganisms, and they induce cytoprotective changes in the host either through enhancement of barrier function, or through the upregulation of cytoprotective host proteins. In this review we focus on a few selected probiotics – a bacterial mixture (VSL), a Gram-negative probiotic (E. coli Nissle 1917), two Gram-positive probiotic bacteria (LGG, L.reuteri), and a yeast probiotic (S. boulardii) – for which sound clinical and mechanistic data is available. Safety of probiotic formulations is also discussed.
Export Options
About this article
Cite this article as:
Petrof O. Elaine, Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (3) . https://dx.doi.org/10.2174/187152309789151977
DOI https://dx.doi.org/10.2174/187152309789151977 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry Stem Cell Factor: A Hemopoietic Cytokine with Important Targets in Asthma
Current Drug Targets - Inflammation & Allergy Carbazole Scaffold in Medicinal Chemistry and Natural Products: A Review from 2010-2015
Current Topics in Medicinal Chemistry Impact of Hydroxyl Radical Modified-Human Serum Albumin Autoantigens in Systemic Lupus Erythematosus
Current Protein & Peptide Science Possible Human Endogenous Cryogens
Current Protein & Peptide Science The Coagulation Cascade in Sepsis
Current Pharmaceutical Design Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Animal Models of Atherosclerosis Progression: Current Concepts
Current Drug Targets - Cardiovascular & Hematological Disorders Pharmacological Approaches for BRCA1/2 Related Breast and Ovarian Cancer: Preclinical Studies and Early Clinical Trials
Current Women`s Health Reviews Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Coumarine Analogues with Antimycobacterial and Immunomodulatory Activity
Current Bioactive Compounds Safety Concerns Related to Hematopoietic Stem Cell Gene Transfer Using Retroviral Vectors
Current Gene Therapy Structure Alteration of Polyketides by Recombinant DNA Technology in Producer Organisms Prospects for the Generation of Novel Pharmaceutical Drugs.
Current Pharmaceutical Biotechnology Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Recent Patents of Nanodevices for Single Cell Immunological Assays
Recent Patents on Nanotechnology Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014
Current Drug Targets Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Editorial [Hot Topic: Pharmaceutical and Cellular Strategies of Recent Advances in Immunotherapy (Executive Editors: George Tuszynski and Mahesh Sharma)]
Current Pharmaceutical Design Low 25OH Vitamin D2 Levels Found in Untreated Alzheimer’s Patients, Compared to Acetylcholinesterase-Inhibitor Treated and Controls
Current Alzheimer Research Preface [Hot Topic:Inflammatory Markers and Mediators: Emerging Therapeutic Targets in Diabetes, Cardiovascular and Metabolic Disorders (Guest Editor: Samuel Dagogo-Jack, MD)].
Current Drug Targets